Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 4, 2004 - Issue 3
Submit an article Journal homepage
47
Views
13
CrossRef citations to date
0
Altmetric
Drug Evaluation

Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly

Angela N Paisley Department of Endocrinology, St Bartholomew’s Hospital, London, EC1A 7BE, UK. [email protected]
,
Peter Trainer Department of Endocrinology, St Bartholomew’s Hospital, London, EC1A 7BE, UK. [email protected]
&
William Drake Department of Endocrinology, St Bartholomew’s Hospital, London, EC1A 7BE, UK. [email protected]
Pages 421-425 | Published online: 03 Mar 2005

Bibliography

  • HOLDAWAY IM, RAJASOORYA C: Epidemiology of acromegaly. Pituitary (1999) 2:29–41.
  • RAJASOORYA C, HOLDAWAY IM, WRIGHTSON P, SCOTT DJ, IBBERTSON HK: Determinants of clinical outcome and survival in acromegaly. Cilia. Endocrinol (1994) 41:95–102.
  • ORME SM, MCNALLY RJQ, CART WRIGHT RA, BELCHETZ PE: Mortality and cancer incidence in acromegaly: a retrospective cohort study. Cilia. Endocrinol Metab. (1998) 83:2730–2734.
  • BATES AS, VAN'T HOFF W, JONES JM,CLAYTON RM: An audit of outcome of treatment in acromegaly. Q. J. Med. (1993) 86:293–299.
  • ABOSCH A, BLAKE TYRELL J, LAMBORN KR, HANNEGAN LT, APPLEBURY CB, WILSON CB: Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J. Cilia. Endocrinol Metab. (1998) 83:3411–3418.
  • HOLDAWAY IM, RAJASOORYA CR, GAMBLE GD, STEWART AW: Long-term treatment outcome in acromegaly. Growth Hopi]. IGF Res. (2003) 13:185–192.
  • GIUSTINA A, BARKAN A, CASANEUVA FF et al.: Criteria for cure of acromegaly: a consensus statement. J. Cilia. Endocrinol Metab. (2000) 85:526–529.
  • TRAINER PJ: Acromegaly-consensus, what consensus? Cilia. Endocrinol Metab. (2002) 87:3534–3536.
  • COLAO A, CUOCOLO A, MARZULLO P et al.: Is the acromegalic cardiomyopathy reversible? Effect of a 5-year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance. Cilia. Endocrinol Metab. (2001) 86:1551–1557.
  • SWEARINGEN B, BARKER FG, KATZNELSON L et al.: Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. I Cilia. Endocrinol Metab. (1998) 83(10):3419–3426.
  • GITTOES NJL, SHEPPARD MC, JOHNSON AP, STEWART PM: Outcome of surgery for acromegaly-the experience of a dedicated pituitary surgeon. Q. J. Med. (1999) 92:741–745.
  • SHEAVES R, JENKINS P, BLACKBURN P et al: Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin. Endocrinol (Off) (1996) 45:407–413.
  • BIERMASZ NR, VAN DULKEN H, ROELFSEMA F: Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. I Clin. Endocrinol Metab. (2000) 85:2476–2482.
  • KOPCHICK JJ, PARKINSON C, STEVENS EC, TRAINER PJ: Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocc Rev (2002) 23(5):623–646.
  • VAN DER LELY AJ, LAMBERTS SWJ, BARKER A et al.: A six week, double blind, placebo controlled study of a growth hormone antagonist, B2036-PEG (Trovert), in acromegalic patients. 80th Annual Meeting of the Endocrine Society New Orleans, LA, USA (1998) Abstract OR4–1.
  • TRAINER PJ, DRAKE WM, KATZNELSON L et al.: Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl. J. Med. (2000) 342:1171–1177.
  • VAN DER LELY AJ, KENT HUTSON R, TRAINER PJ et al.: Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet (2001) 358:1754–1759.
  • FREDA PU: Somatostatin analogs in acromegaly. Clin. Endocrinol Metab. (2002) 87:3013–3018.
  • ABS R, VERHELST J, MAITER D et al.: Cabergoline in the treatment of acromegaly: a study in 64 patients.' Clin. Endocrinol Metab. (1998) 83:374–378.
  • HANSEN I, TSALIKIAN E, BEAUFRERE B, GERICH J, HAYMOND M, RIZZA R: Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. J. Phys. (1986) 250:E269–E273.
  • RANDLE PJ, GARLAND PB, HALES CN, NEWSHOLME EA. The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbance of diabetes mellitus. Lancet (1963) 1:785–789.
  • ROSE DR, CLEMMONS DR: Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horn]. IGF Res. (2002) 12:418–424.
  • DRAKE WM, ROWLES SV, ROBERTS ME et al.: Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur: .1. Endocrinol (2003) 149:521–527.
  • CLEMMONS DR, BARKAN AL, MELMED S et al: Pegvisomant improves glucose homeostasis in patients with acromegaly previously treated with octreotide LAR. 85th Annual Meeting of the Endocrine Socieh,, Philadelphia, PA, USA (2003) P2–341.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.